AstraZeneca Pharma India has appointed Praveen K Mittal as Director - Corporate Affairs, effective July 6, 2026, strengthening its senior management leadership. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee, and is classified as a full-time position. This strategic move aims to leverage Mittal's extensive experience in corporate affairs, government relations, and public policy to drive the company's stakeholder engagement and policy advocacy initiatives.

Appointment Details

The company disclosed the appointment under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The position is classified as Senior Management Personnel, necessitating detailed disclosures as per SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026. The term of the appointment is full-time employment, commencing from the specified effective date.

Profile of the Appointee

Praveen Kumar Mittal is a seasoned leader with nearly 30 years of experience across healthcare, medical technology, trade promotion, and industry advocacy. Prior to this role, he served as the Executive Director of the Export Promotion Council for Medical Devices (EPCMD), where he was responsible for policy advocacy, stakeholder engagement, and international market development. Before his tenure at EPCMD, he spent over 18 years with the Federation of Indian Chambers of Commerce & Industry (FICCI), most recently as Assistant Secretary General and Head of the Healthcare Division.

Key Professional Highlights

Mittal has played a pivotal role in establishing industry platforms and building strategic partnerships across government and industry. He was also instrumental in the establishment of the Ayush Export Promotion Council (AYUSHEXCIL), where he served as Honorary Director. His deep expertise in public policy and government engagement is supported by extensive international exposure across North America, Europe, and Asia.

AstraZeneca Pharma India Ltd has closed its trading window for dealing in its equity shares starting June 16, 2026. The closure is intended to prevent insider trading and ensure compliance with regulatory standards ahead of its quarterly financial announcement. The window will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ending June 30, 2026.

Regulatory Compliance

The decision to close the trading window aligns with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Additionally, the move adheres to astrazeneca pharma 's internal Code of Conduct for Prevention of Insider Trading. These regulations mandate a blackout period to restrict trading by designated insiders when they are in possession of unpublished price-sensitive information.

Timeline for Reopening

The trading window will not reopen immediately upon the release of the Q1FY27 results. Instead, it will remain closed for an additional 48 hours following the declaration of the unaudited financial results. This buffer period is standard practice to allow the information to be fully assimilated by the market before trading resumes for insiders.

The company has communicated this schedule to the National Stock Exchange of India Ltd and BSE Limited to ensure the information is on public record.